Peak width of skeletonized mean diffusivity and cognitive performance in cerebral amyloid angiopathy.
cerebral amyloid angiopathy (CAA)
cerebral small vessel disease
cognitive functions
diffusion-weighted imaging
peak width of skeletonized mean diffusivity (PSMD)
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2023
2023
Historique:
received:
09
01
2023
accepted:
20
03
2023
medline:
20
4
2023
pubmed:
20
4
2023
entrez:
20
04
2023
Statut:
epublish
Résumé
Cerebral Amyloid Angiopathy (CAA) is a cerebral small vessel disease that can lead to microstructural disruption of white matter (WM), which can be measured by the Peak Width of Skeletonized Mean Diffusivity (PSMD). We hypothesized that PSMD measures would be increased in patients with CAA compared to healthy controls (HC), and increased PSMD is associated with lower cognitive scores in patients with CAA. Eighty-one probable CAA patients without cognitive impairment who were diagnosed with Boston criteria and 23 HCs were included. All subjects underwent an advanced brain MRI with high-resolution diffusion-weighted imaging (DWI). PSMD scores were quantified from a probabilistic skeleton of the WM tracts in the mean diffusivity (MD) image using a combination of fractional anisotropy (FA) and the FSL Tract-Based Spatial Statistics (TBSS) algorithm (www.psmd-marker.com). Within CAA cohort, standardized z-scores of processing speed, executive functioning and memory were obtained. The mean of age and sex were similar between CAA patients (69.6 ± 7.3, 59.3% male) and HCs (70.6 ± 8.5, 56.5% male) ( Peak Width of Skeletonized Mean Diffusivity is increased in CAA, and it is associated with worse cognitive scores supporting the view that disruption of white matter has a significant role in cognitive impairment in CAA. As a robust marker, PSMD can be used in clinical trials or practice.
Sections du résumé
Background
UNASSIGNED
Cerebral Amyloid Angiopathy (CAA) is a cerebral small vessel disease that can lead to microstructural disruption of white matter (WM), which can be measured by the Peak Width of Skeletonized Mean Diffusivity (PSMD). We hypothesized that PSMD measures would be increased in patients with CAA compared to healthy controls (HC), and increased PSMD is associated with lower cognitive scores in patients with CAA.
Methods
UNASSIGNED
Eighty-one probable CAA patients without cognitive impairment who were diagnosed with Boston criteria and 23 HCs were included. All subjects underwent an advanced brain MRI with high-resolution diffusion-weighted imaging (DWI). PSMD scores were quantified from a probabilistic skeleton of the WM tracts in the mean diffusivity (MD) image using a combination of fractional anisotropy (FA) and the FSL Tract-Based Spatial Statistics (TBSS) algorithm (www.psmd-marker.com). Within CAA cohort, standardized z-scores of processing speed, executive functioning and memory were obtained.
Results
UNASSIGNED
The mean of age and sex were similar between CAA patients (69.6 ± 7.3, 59.3% male) and HCs (70.6 ± 8.5, 56.5% male) (
Discussion
UNASSIGNED
Peak Width of Skeletonized Mean Diffusivity is increased in CAA, and it is associated with worse cognitive scores supporting the view that disruption of white matter has a significant role in cognitive impairment in CAA. As a robust marker, PSMD can be used in clinical trials or practice.
Identifiants
pubmed: 37077322
doi: 10.3389/fnins.2023.1141007
pmc: PMC10106761
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1141007Informations de copyright
Copyright © 2023 Horn, Gokcal, Becker, Das, Schwab, Zanon Zotin, Goldstein, Rosand, Viswanathan, Polimeni, Duering, Greenberg and Gurol.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Neurol. 2013 Aug;12(8):822-38
pubmed: 23867200
J Neurosci. 2014 Nov 12;34(46):15425-36
pubmed: 25392509
Alzheimers Dement. 2020 Dec;16(12):1714-1733
pubmed: 33030307
J Neurosci. 2011 Jan 26;31(4):1204-12
pubmed: 21273405
Neuroimage Clin. 2020;27:102280
pubmed: 32521475
Neurology. 2016 Feb 9;86(6):505-11
pubmed: 26747886
Int J Stroke. 2023 Jan;18(1):78-84
pubmed: 35473418
AJNR Am J Neuroradiol. 2021 May;42(5):875-881
pubmed: 33664113
Stroke. 2020 Jan;51(1):29-37
pubmed: 31752614
Neuroimage. 2006 Jul 1;31(3):1116-28
pubmed: 16545965
Neurology. 2014 Jul 22;83(4):304-11
pubmed: 24951477
Alzheimers Dement (Amst). 2019 Feb 26;11:191-204
pubmed: 30859119
J Neurosci. 2010 Jun 2;30(22):7569-74
pubmed: 20519531
Front Neurosci. 2013 Mar 12;7:31
pubmed: 23486659
Front Neurosci. 2022 Nov 11;16:1051038
pubmed: 36440281
Neurology. 2017 Jun 6;88(23):2162-2168
pubmed: 28476760
J Intern Med. 2004 Sep;256(3):183-94
pubmed: 15324362
Neurology. 1993 Oct;43(10):2073-9
pubmed: 8413970
Neurology. 2021 Mar 23;96(12):e1646-e1654
pubmed: 33536272
Lancet Neurol. 2009 Feb;8(2):165-74
pubmed: 19161908
Brain. 2016 Dec;139(Pt 12):3151-3162
pubmed: 27645801
Neurology. 2010 Apr 27;74(17):1346-50
pubmed: 20421578
Neuroimage. 2008 Aug 15;42(2):1032-44
pubmed: 18602840
Neuroimage. 2019 Nov 15;202:116137
pubmed: 31473352
Brain. 2015 Jan;138(Pt 1):179-88
pubmed: 25367025
Neurology. 2001 Feb 27;56(4):537-9
pubmed: 11222803
Stroke. 2006 Jul;37(7):1759-64
pubmed: 16763176
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
Ann Neurol. 2013 Apr;73(4):529-36
pubmed: 23424091
J Am Heart Assoc. 2019 Feb 5;8(3):e011288
pubmed: 30717612
Neuroimage. 2009 Mar;45(1 Suppl):S173-86
pubmed: 19059349
Brain. 2015 Aug;138(Pt 8):2126-39
pubmed: 26115675
Hum Brain Mapp. 2016 Jan;37(1):300-10
pubmed: 26466741
Neuroimage. 2016 Jan 15;125:1063-1078
pubmed: 26481672
Stroke. 2018 Oct;49(10):2330-2336
pubmed: 30355109
Ann Neurol. 2016 Oct;80(4):581-92
pubmed: 27518166
Front Psychiatry. 2020 May 04;11:342
pubmed: 32425831